This study was performed in order to determine concentration-effect, and graded and quanta1 dose-response relationships for the clinical administration of intravenous (IV) lidocaine to patients with neuropathic pain. Thirteen patients were administered 500 mg of IV lidocaine at a rate of 8.35 mg/min over 60 min. Visual analog pain scores and venous blood samples were obtained concomitantly at 10 min intervals for 60 min. Blood samples were also obtained for determination of serum and serum water lidocaine concentrations at the onset of analgesia and at the time complete pain relief was attained. Lidocaine concentrations were determined by gas chromatography.
This study was performed in order to determine concentration-effect, and graded and quanta1 dose-response relationships for the clinical administration of intravenous (IV) lidocaine to patients with neuropathic pain. Thirteen patients were administered 500 mg of IV lidocaine at a rate of 8.35 mg/min over 60 min. Visual analog pain scores and venous blood samples were obtained concomitantly at 10 min intervals for 60 min. Blood samples were also obtained for determination of serum and serum water lidocaine concentrations at the onset of analgesia and at the time complete pain relief was attained. Lidocaine concentrations were determined by gas chromatography.
Graded dose-response curves were prepared individually and for the group as a whole, and a quanta1 dose-response curve was prepared for the entire group. The dose-response relationship for IV lidocaine was characterized by large increases in pain relief for concomitant minimal increases in dosage. The difference between the ED,, (372.0 mg) and the ED,, (416.5 mg) was 44.5 mg of lidocaine (5.3 min of infusion). The concentration-effect relationship was also steep with pain scores abruptly decreasing over a range of 0.62 pg/mL of lidocaine. Interestingly, the free concentration of lidocaine had no better correlation with the onset of analgesia or the attainment of complete analgesia than the serum concentration of lidocaine. This suggests that the mechanism of analgesia to IV lidocaine may not be based upon a conventional concentration-effect relationship.
In conclusion, the results of this study suggest that the analgesic response to IV lidocaine is best characterized by a precipitous 'break in pain" over a narrow dosage and concentration range.
(Anesth Analg 1996;82:91-7)
T he intravenous (IV) administration of lidocaine has long been used to provide analgesia in patients with neuropathic pain of varying etiologies (l-4). Unfortunately, basic pharmacologic relationships, such as dose-response curves, have not been fully defined. Previous work by Boas et al. (1) used a methodology involving a bolus injection of 3 mg/kg of lidocaine followed by a continuous infusion of 4 mg/min. The onset of analgesia was effectively immediate, and steady-state blood concentrations were achieved rapidly. Thus, neither dose-response relationships nor concentration-effect relationships could be defined. Furthermore, the study did not examine the significance of free versus total serum concentrations of lidocaine upon the production of analgesia. [Free drug concentration is generally accepted as a more accurate reflection of the active concentration (5j.l
The object of this study was to define concentrationeffect and dose-response relationships for the clinical administration of IV lidocaine for neuropathic pain states of varying etiology. The setting and the administration of IV lidocaine for this study was kept as close as possible to clinical practice. The correlation of free versus total serum concentrations of lidocaine and various stages of analgesia was also investigated.
Methods
Patients with neuropathic pain were recruited to participate in this preliminary study without regard for standardization of diagnosis (i.e., central versus peripheral neuralgia, sympathetically maintained pain versus nonsympathetic mechanism, etc.). Participants were selected irrespective of gender and age. Patients with preexisting hepatic or renal disease were excluded from the study. Each patient had had neuropathic pain for at least 6 mo prior to enrollment. No immediately after the IV infusion. The entire battery of tests was again completed at 1 and 2 wk postinfusion.
IV lidocaine was administered in a controlled environment with resuscitative drugs and equipment immediately available. IV catheters were inserted in contralateral limbs for the administration of lidocaine and the withdrawal of blood samples. Procaine was used to provide analgesia for catheter insertion via skin infiltration. Lidocaine was administered IV at a rate of 8.35 mg/min (500 mg in 250 mL of normal saline over 60 min). The effect of lidocaine on the intensity of neuropathic pain was assessed by subjective bioassay using a lo-cm visual analog scale. Pain scores were obtained before starting the infusion and at lo-min intervals until completion of the infusion.
A brief neurologic examination was performed prior to the administration of IV lidocaine and every 10 min during the infusion until completion. Neurologic examination included assessment of alertness, orientation, pupillary size, extraocular muscle function, nystagmus, VIIIth cranial nerve function, gross motor strength, reflexes, and coordination.
The complete examination required 2-3 min to perform. Patients were told to report immediately any subjective responses to the infusion (light-headedness, circumoral numbness, etc.) to the observer.
Blood samples (3 mL) to determine lidocaine concentration were obtained prior to the IV infusion and at 10, 20, 30, 40, 50, and 60 min during the infusion. Samples were stored in heparinized tubes at -20°C until required for analysis. Additional blood samples (10 mL) to determine serum and serum water concentrations of lidocaine were obtained at initial onset of analgesia and when complete pain relief was attained. These samples were allowed to clot at room temperature, centrifuged to obtain serum, and stored as above. Serum pH was adjusted to physiologic pH using microliter quantities of 0.1 M HCI or 0.1 M NaOH as required. Serum water was then obtained using an ultrafiltration technique (8), and the percentage of protein binding of lidocaine was calculated.
Lidocaine concentrations in whole blood, serum, and serum water were determined using gas chromatography and reported as micrograms of lidocaine HCl per milliliter of fluid (9). Assay variability was typically ~5% over the concentration range of the samples.
Graded dose-response curves were prepared individually and for the entire group of patients, and subjected to logarithmic regression analysis. A quanta1 dose-response curve was constructed for achievement of complete analgesia by plotting the cumulative frequency distribution of responders versus log dose. ED,, was estimated by means of a quadratic regression equation as there was no empiric observation of the ED,,. The percent of patients attaining complete pain relief was the dependent variable. The dose of lidocaine and the square of the dose were the independent variables.
A plot of lidocaine concentration versus time was prepared, and logarithmic regression was performed. Concentration-effect curves were prepared individually for each patient and for the entire group.
All patients were included in statistical analyses where appropriate.
The median was used as a measure of central tendency for ordinal data (visual analog pain scores and scores from the short-form McGill Pain Questionnaire and the Multidimensional Pain Inventory). The Wilcoxon signed rank test was used to determine differences between paired groups for ordinal data. Mean t SD are reported for interval data. The paired Student's t-test was used to determine differences between group means for interval data. For all statistical analyses, P < 0.05 was considered significant.
Results
Thirteen patients were enrolled in the study. Ten patients achieved complete pain relief. The "incomplete" responders obtained 55% (Patient 3), 40% (Patient 7), and 62% Patient 9) relief from their baseline pain at the end of infusion. The age, gender, diagnosis, initial pain score prior to infusion, and dose of lidocaine for complete analgesia for each patient are listed in Table 1 .
The time of initial onset of analgesia (14.8 min 2 6.6) and the calculated corresponding dose of lidocaine (123.0 mg t-55.0) exhibited significant interpatient variability (coefficient of variation [CV] = 0.45). However, the time of onset of complete analgesia (45 min 2 8.6) and the calculated corresponding dose of lidoCaine (374.9 mg 2 22.7) exhibited minimal interpatient variability (CV = 0.2). Figure 1 . The graded doseresponse curve is described using logarithmic regression analysis by the equation: y = 18.845 -43.946 * log(x); X2 = 0.968. The data point for the 500-mg dose of lidocaine (median visual analog pain score = 0) was excluded in the regression analysis as a median pain score of 0 was already achieved at a lidocaine dose of 416.5 mg.
The quanta1 dose-response relationship for IV lidoCaine is shown in Figure 2 . This relationship is described using quadratic regression analysis by the equation:
% patients with complete analgesia = -9.8 -(0.062 X dose) + (0.0006 X dose'); X2 = 0.93.
Using this equation, the ED,, was calculated to be 372.0 mg of lidocaine. This agrees quite well with the mean calculated dose of lidocaine (374.9 mg k 22.7) at the time complete analgesia was achieved.
The slope of the linear portion of the quanta1 doseresponse curve for IV lidocaine is extremely steep (Fig.  2) . The difference between the EDso (372.0 mg) and the ED,, (416.5 mg) was 44.5 mg of lidocaine (5.3 min of infusion). The difference between the ED,, (330.0 mg) and the ED,, (the end-points of the linear portion of the dose-response curve) was 86.5 mg of lidocaine (10.4 min of infusion).
A plot of lidocaine concentration as a function of time of infusion is shown in Figure 3 . There was appreciable variation in the lidocaine concentrations in whole blood at each time point. (CV at each time point -0.3) Concentration-effect curves were prepared individually for each patient (Fig. 4) and for the group as a whole (Fig. 1) 4) : (a) curves with a precipitous decrease in pain score over a narrow concentration range with or without the immediate onset of analgesia (n = lo), and (b) partial analgesic response curves with a similar, abrupt decrease in pain score over a narrow concentration range (n = 3). The plot for the entire group of patients demonstrated that pain scores decreased rapidly over a narrow concentration range of 0.62 pg/mL of lidocaine (Fig. 1) .
The total serum concentration of lidocaine at the initial onset of analgesia (2.43 pg/mL + 1.01) was highly variable (CV = 0.42). The total serum concentration of lidocaine at the time of onset of complete analgesia (3.79 pg/mL + 1.00) was less variable (CV = 0.26) ( Table 2 ). The mean difference between the lidocaine concentration associated with the initial onset of analgesia and complete analgesia Wend complete analgesia -[Serum] onset) (a measure of the range of analgesic concentrations) was 1.32 pg/mL k 0.69 (CV = 0.52) ( Table 2 ). Thus the range of the analgesic concentrations between the initial onset of analgesia and the onset of complete analgesia was appreciable and highly variable.
The free concentration of lidocaine at the initial onset of analgesia (0.67 pg/mL +-0.26) was also highly variable (CV = 0.4), although variability diminished by the onset of complete analgesia (1.28 pg/mL 2 0.35; CV = 0.28) ( Table 2) 52.7%-77.4%). Both ranges of protein binding are consistent with previously published norms for lidocaine over the concentration range of the samples (10). There was little interpatient variability in the degree of protein binding at initial onset of analgesia and when complete analgesia was achieved (both CV = 0.10). The difference in the degree of protein binding between the two time points was statistically significant (P < 0.041, coinciding with the usual increase in the free lidocaine concentration as higher drug concentrations are achieved (10). Scoring of the McGill Pain Questionnaire before and after receiving an infusion of IV lidocaine demonstrated an analgesic effect (Table 3) (P < 0.008). However, a significant analgesic effect was not seen at 1 and 2 wk postinfusion. The effect of analgesia upon performance of activities of daily living was measured With respect to subjective responses, 6 of 13 patients reported light-headedness at some time during the infusion. The range of lidocaine concentrations in whole blood was 0.95 pg/mL to 3.08 pg/mL. Lightheadedness resolved spontaneously in two patients. Two patients complained they felt "drunk" (whole blood lidocaine concentrations = 1.50 pg/mL and 4.01 pg/mL), although appearing to be alert and oriented. Two patients appeared somewhat sedated (whole blood lidocaine concentrations = 2.34 pg/mL and 4.01 At no time was it necessary to adjust patients' rate of infusion because of subjective complaints of toxicity.
Discussion
The results of this study demonstrate that the analgesic response to IV lidocaine in the treatment of neuropathic pain is characterized by large increases in pain relief for very minimal increases in dosage and blood concentration. The slopes of both the graded doseresponse curve (entire group; Fig. 1 ) and quanta1 doseresponse curve (linear portion; Fig. 2) were very steep.
The slope of the linear portion of the quanta1 doseresponse curve was almost reminiscent of an "all-ornone" phenomenon. The difference between the EDsa (372.0 mg) and the ED,, (416.5 mg) was 44.5 mg of lidocaine (5.3 min of infusion). The concentrationeffect relationship was also steep with pain scores abruptly decreasing over a range of 0.62 pg/mL of lidocaine (Fig. 1) .
Free drug concentration is generally regarded as a more accurate reflection of the active concentration (5). In the present study, the free concentration of lidocaine had no better correlation with the onset of analgesia or the attainment of complete analgesia than Table 2 ). This suggests that the mechanism of analgesia to IV lidocaine may not be based upon a conventional concentration-effect relationship. It is worthy of note that the lack of correlation between plasma concentrations and the symptomatic effect of oral mexiletine (a lidocaine cogener) previously was discounted as a false-negative result (11). Yet, the work of Brose and Cousins (12) suggests that target blood concentrations may be important in achieving analgesia with continuous subcutaneous infusions of lidocaine, though free lidocaine concentrations were not measured. Steady-state concentrations were not achieved in the present study because of the use of a fixed-rate infusion, which allowed definition of dose-response relationships and examination of concentration-effect relationships over a range of lidocaine concentrations. However, the relationship of free drug concentration, as a more accurate reflection of the active concentration, should have held, irrespective of the attainment of steady-state concentrations, as lidocaine concentrations were increasing relatively slowly, particularly at the time of attainment of complete analgesia.
Several authors have documented the production of protracted analgesia (days to weeks) with administration of IV lidocaine (2,4,13) which also suggests the presence of an unconventional pharmacodynamic response to blood or serum concentrations of lidocaine as the half-life of lidocaine is only 1.6 h (5). In the present study, the production of protracted analgesia was examined by administration of the short-form McGill Pain Questionnaire, and any concomitant increase in functional activity was assessed using the Multidimensional Pain Inventory. There was no evidence of protracted analgesia or an increase in functional activity when measured at 1 and 2 wk postinfusion. This is in contrast to the study of Edwards et al.
(2) where 33% of patients responding to IV lidocaine had pain relief of greater than 1 wk duration. The reasons for this discrepancy are obscure, but are perhaps related to the smaller number of patients (n = 13) in this preliminary study examining blood concentrations as compared to the larger descriptive study of Edwards et al. (Table 1 ) or a preponderance of central or peripheral pathologies in these incomplete responders (Table 1) . [Various authors have suggested the predominance of central (1,13,16) versus peripheral (17) analgesic mechanism(s) for IV lidocaine as its site of action is not clear. No conclusions regarding the predominance of one mechanistic site or another can be drawn from the present findings due to the small total number of patients and the preponderance of patients with a probable peripheral origin for their pain.]
A possible criticism of this preliminary study is the lack of methodology to exclude placebo responders. Patients included in this study were referred to the Pain Center specifically to receive infusions of IV lidocaine as it is a conventional therapy for the treatment of neuropathic pain. Regardless of a response to a placebo infusion, patients would have received IV lidocaine as therapy for their neuropathic pain. Thus we thought it unwise to include placebo infusions (18).
In summary, the results of this study suggest that large increases in analgesic response are achieved for very minimal increases in dosage when IV lidocaine is used for the treatment of neuropathic pain. The slopes of both the graded (entire group) and quanta1 (linear portion) dose-response curves were very steep. The slope of the linear portion (ED,, L330.0 mgl through ED,, [416.5 mgl) of the quanta1 dose-response curve was almost reminiscent of an "all-or-none" phenomenon (Fig. 2) . The concentration-effect relationship was also steep, with pain scores abruptly decreasing over a range of 0.62 pg/mL of lidocaine (Fig. 1) . The free concentration of lidocaine was no better correlated with the onset of analgesia or the attainment of complete analgesia than the serum concentration of lidoCaine. This suggests that the pharmacodynamic response to IV lidocaine may not be predicated upon a conventional concentration-effect relationship. Corroboration of this hypothesis and elucidation of its implications are important topics for further research. In conclusion, the results of this study suggest that the analgesic response to IV lidocaine for the treatment of 
